Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J F Merola

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Clinical Rheumatology|May 2, 2021
Healthcare utilization and costs among patients with psoriasis and psoriatic arthritis in the USA-a retrospective study of claims data from 2009 to 2020J F Merola, N Dennis, S D Chakravarty, et al.
The British Journal of Dermatology|April 29, 2021
Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy studyA B Gottlieb, J F Merola, K Reich, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 22, 2017
Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3)A Menter, R B Warren, R G Langley, et al.
Clinical and Experimental Dermatology|February 6, 2016
Novel application of high-dose rate brachytherapy for severe, recalcitrant palmoplantar pustulosisD Timerman, P M Devlin, V E Nambudiri, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 10, 2020
Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studiesJ F Merola, K A Papp, P Nash, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 4, 2022
Definitions of remission in psoriasis: a systematic literature review from the National Psoriasis FoundationD M W Balak, L M Perez-Chada, L N Guo, et al.
Scandinavian Journal of Rheumatology|March 18, 2022
Increased prevalence of sleep disturbance in psoriatic arthritis is associated with inflammatory and non-inflammatory measuresM Skougaard, Z R Stisen, T S Jørgensen, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 7, 2020
The National Psoriasis Foundation psoriasis treatment targets in real-world patients: prevalence and association with patient-reported outcomes in the Corrona Psoriasis RegistryJ F Merola, L M Perez Chada, M Siegel, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 12, 2024
Tofacitinib efficacy, patient-reported outcomes and safety in patients with psoriasis and a medical history of psoriatic arthritis: Pooled analysis of two Phase III studiesH Bachelez, C E M Griffiths, K A Papp, et al.
The British Journal of Dermatology|April 15, 2018
A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi processL Thorlacius, J R Ingram, B Villumsen, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Clinical Rheumatology|May 2, 2021
Healthcare utilization and costs among patients with psoriasis and psoriatic arthritis in the USA-a retrospective study of claims data from 2009 to 2020J F Merola, N Dennis, S D Chakravarty, et al.
The British Journal of Dermatology|April 29, 2021
Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy studyA B Gottlieb, J F Merola, K Reich, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 22, 2017
Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3)A Menter, R B Warren, R G Langley, et al.
Clinical and Experimental Dermatology|February 6, 2016
Novel application of high-dose rate brachytherapy for severe, recalcitrant palmoplantar pustulosisD Timerman, P M Devlin, V E Nambudiri, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 10, 2020
Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studiesJ F Merola, K A Papp, P Nash, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 4, 2022
Definitions of remission in psoriasis: a systematic literature review from the National Psoriasis FoundationD M W Balak, L M Perez-Chada, L N Guo, et al.
Scandinavian Journal of Rheumatology|March 18, 2022
Increased prevalence of sleep disturbance in psoriatic arthritis is associated with inflammatory and non-inflammatory measuresM Skougaard, Z R Stisen, T S Jørgensen, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 7, 2020
The National Psoriasis Foundation psoriasis treatment targets in real-world patients: prevalence and association with patient-reported outcomes in the Corrona Psoriasis RegistryJ F Merola, L M Perez Chada, M Siegel, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 12, 2024
Tofacitinib efficacy, patient-reported outcomes and safety in patients with psoriasis and a medical history of psoriatic arthritis: Pooled analysis of two Phase III studiesH Bachelez, C E M Griffiths, K A Papp, et al.
The British Journal of Dermatology|April 15, 2018
A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi processL Thorlacius, J R Ingram, B Villumsen, et al.
Pageof 4